Comparison Of Immunogenicity Between The Proposed Pegfilgrastim Biosimilar Myl-1401h And Reference Pegfilgrastim

C Waller,Gopinath M. Ranganna,Eduardo Pennella,Leonard A. Mattano, Chien Chang Loa,Charles Donnelly,Mark Shiyao Liu, Heather Watson, Julien St-Jean,Sanjukta Chatterjee, Vivek Nayak,Nilanjan Sengupta,Mudgal A. Kothekar,Abhijit Barve

BLOOD（2017）

引用 23|浏览5

暂无评分

摘要

Introduction: Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is indicated for reduction of incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. Here, the immunogenicity data for MYL-1401H, a proposed biosimilar of pegfilgrastim, from the clinical studies will be presented.

查看译文

关键词

reference pegfilgrastim,immunogenicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要